… ) vaccination had been published by June 2016.1–3 Initially most of these analyses focused
on the health and economic benefits of HPV vaccination … HPV vaccines (the bivalent vaccine …

… vaccination in adult women. In this study, we evaluate the clinical benefit and cost-effectiveness
of vaccinating women from age 17 to 25 years compared to no vaccination in these age …

… vaccine coverage and the effectiveness of cervical cancer prevention. The objective of this
study was to systematically review … schedules for human papillomavirus (HPV) vaccine and to …

… programs have demonstrated significant clinical and cost benefits.[46,47] However, these …
of our systematic review and meta-analysis, we recommend expanding the HPV vaccination …

… systematic review, the epidemiological and economic impacts of HPV are evaluated. Methods:
A literature … of view and analyze whether vaccination can be costeffective. The secondary …

… The quadrivalent and bivalent human papillomavirus (HPV) vaccines are now licensed in
several countries. We compared the cost-effectiveness of the HPV vaccines to provide …

… Drolet, M.; Bénard, É.; Pérez, N.; Brisson, M.; HPV Vaccination Impact Study Group. … of
human papillomavirus vaccination programmes: Updated systematic review and meta-analysis. …

… This systematic review shows that there is no evidence from long-term follow-up that
vaccine protection following vaccination for HPV types 16 and 18 decreases. While persistent …

… We have performed a systematic review of all randomized controlled trials in which HPV …
recent systematic review also reported barriers to preventive human papillomavirus vaccination …

… A systematic review of participants in six clinical trials who received only … study, we only
assessed the effect of HPV vaccination on cervical cancers. If we also accounted for the vaccine …